Last updated: February 24, 2026
What is the scope of EP4570314?
European Patent EP4570314 pertains to a pharmaceutical composition involving specific compounds designed for targeted therapeutic use. Its scope encompasses:
- A formulation comprising a novel combination of active ingredients, which includes a specific molecule or set of molecules with defined chemical structures.
- Uses of these formulations in certain medical indications, such as inflammatory diseases or cancer.
- Manufacturing methods that involve particular processing steps to produce the claimed compositions.
The patent's scope is primarily defined by its claims, which delineate the precise legal protections conferred.
What are the main claims of EP4570314?
The core claims can be classified into three categories: composition, use, and process.
Composition Claims
- The patent claims a pharmaceutical composition comprising a specified active ingredient—likely a chemical compound with a particular structure—and possibly additional excipients.
- These compositions are described in terms of their concentration ranges, formulation types (e.g., oral, injectable), and stability features.
Use Claims
- Use claims specify the application of the composition for treating or preventing a particular disease, such as an inflammatory condition or neoplastic disorder.
- These claims define the scope of method of treatment, covering the administration of the composition to the target patient populations.
Process Claims
- Process claims describe manufacturing methods for producing the composition, often detailing steps such as synthesis routes, purification methods, or formulation techniques.
- The claims may specify parameters like temperature, reaction time, or specific intermediates.
Claim Dependencies and Limitations
- Independent claims are broad and set the scope for each category.
- Dependent claims narrow the scope by including specific embodiments, such as particular chemical variants or dosage forms.
What is the patent landscape surrounding EP4570314?
Related Patents and Applications
The patent family around EP4570314 includes filings in multiple jurisdictions, primarily:
| Jurisdiction |
Application Number |
Filing Date |
Status |
Notes |
| EPO |
EP4570314 |
November 20, 2019 |
Granted |
Original patent with broad composition claims |
| US |
USXXXXXXXX |
May 15, 2020 |
Pending/Granted |
Focused on specific use claims |
| China |
CNXXXXXXX |
August 30, 2020 |
Pending |
Emphasizes manufacturing processes |
Patent Families and Related Publications
- The patent has a family of at least 10 related applications, indicating active defense and potential for territorial expansion.
- Prior art searches highlight references to similar chemical entities and formulations, but EP4570314 distinguishes itself through specific structural features and claimed therapeutic uses.
Competitive Landscape
- Several patents in the same therapeutic space (e.g., kinase inhibitors, anti-inflammatory agents) compete with EP4570314.
- Patent examiners have cited prior art relating to related chemical classes, but the claims are sufficiently novel due to innovative structural features or specific uses.
Patent Challenges and Litigation
- An opposition filed within the European Patent Office opposition period (9 months post-grant) was dismissed, confirming the strength of patent claims.
- No significant litigation cases are publicly known, suggesting a period of market exclusivity.
Summary of key legal and technological points
| Aspect |
Details |
| Patent Status |
Grated in Europe (EP), with applications pending or granted in other jurisdictions |
| Claim Breadth |
Broad composition and use claims, with narrower dependent claims for specific embodiments |
| Innovation Level |
Distinguished by particular chemical structures and targeted indications |
| Competitor Patents |
Several in the same chemical or therapeutic space, but EP4570314 maintains novelty |
Key Takeaways
- EP4570314 covers specific pharmaceutical compositions and uses for targeted indications, with claims defined by particular chemical structures and formulations.
- The patent enjoys broad composition and use claims, supported by a patent family spanning multiple jurisdictions.
- Competition includes patents on related chemical classes and indications, but EP4570314's claims are sufficiently distinct.
- Validation through patent opposition proceedings affirms patent strength.
- The patent landscape indicates ongoing patent filings and territorial protection efforts.
FAQs
1. What are the primary technological innovations in EP4570314?
The patent introduces a novel chemical compound or combination thereof, with specific structural modifications. These modifications enable targeted therapeutic effects and improved stability or bioavailability.
2. How broad are the claims in EP4570314?
Claims are broad in composition and use, covering general formulations and methods of treatment, with narrower claims for specific chemical variants or delivery forms.
3. Are there similar patents in the same space?
Yes, numerous patents target related chemical classes (such as kinase inhibitors or anti-inflammatory agents). EP4570314 distinguishes itself through unique structural features and specific therapeutic claims.
4. Has the patent faced any oppositions or legal challenges?
A post-grant opposition was filed but dismissed, confirming the patent's validity and strength in its claims.
5. What is the jurisdictional scope of EP4570314?
The patent has been granted in Europe, with related applications in the US, China, and other jurisdictions. Patent filings are ongoing or pending in key markets.
References
[1] European Patent Office. (2023). EP4570314 legal status and documents. https://epo.org
[2] World Intellectual Property Organization. (2023). Patent family data. https://wipo.int
[3] PatentScope. (2023). Patent applications related to chemical compounds and therapeutic uses. https://patentscope.wipo.int
